ArticleJournal of immunology (Baltimore, Md. : 1950)2025
The complement regulator CD55 modulates TLR9 signaling and supports survival in marginal zone B cells.
Article in Journal of immunology (Baltimore, Md. : 1950), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- C5 inhibition restores B cell homeostasis and humoral immunity in CHAPLE disease patients.Journal of human immunity · 2026Article
- CD55-expressing myeloid-derived suppressor cells (MDSCs) drive cancer immunoevasion.Journal for immunotherapy of cancer · 2026Article
- Transcriptomic profile of the hippocampus of rat strains with contrasting nervous system excitability.PloS one · 2026Article
Corrections and comments
- Update of
Authors and funding
8 authors.
Funding
Abstract
Marginal zone (MZ) B cells bridge innate and adaptive immunity by sensing bloodborne antigens and producing rapid antibody and cytokine responses. When unregulated, MZ B cells are associated with autoimmunity. CD55 is a membrane-bound complement regulator that interferes with complement activation and is another important component of innate and adaptive immunity. MZ B cells express low CD55 in both mice and humans, but the role of CD55 in MZ B cell function is unknown. Using germline knockout (KO) mice, we found that similar numbers of MZ B cells were initially established in 3-wk-old CD55-deficient mice compared with wild-type mice. However, MZ B cells failed to accumulate as mice aged and underwent increased apoptosis independent of alternative complement activation. Following ex vivo stimulation of MZ B cells through TLR9 (Toll-like receptor 9), we observed increased interleukin-6 expression in CD55 KO MZ B cells. In addition, CD55 KO mice exhibited reduced total IgG response following in vivo administration of TLR9 agonist. These findings provide new insights into the role of CD55 in MZ B cell survival and B cell function.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.